patients

Glaxo is in settlement talks with attorneys for an estimated 1,000 former Avandia users.

Glaxo shares are down 0.42%, or $0.18, to $43.06.

Shares of GlaxoSmithKline (GSK) are down after Bloomberg, citing a lawyer for the patients, reported that the drug maker is set to resolve 1,000 more lawsuits over medicines, including the diabetes drug Avandia.

Health care shares are lower in mid-session trading while Xoma (XOMA) tumbles after disappointing results from a clinical trial. The company is down nearly 30% in early trading, after it said late Tuesday its Phase 2b trial of XOM

The company has an unapproved drug, Protectan, which has so far shown to be effective in treating radiation sickness up to 48 hours after the initial exposure.

Chief Executive Michael Fonstein said Monday, "There are no approved drugs in this area, and we definitely believe we have a very potent remedy. Obviously, our drug is highly relevant. However, it is unlicensed.

Shares of Cleveland BioLabs (NASDAQ:CBLI) jumped sharply for the second day in a row, and are now trading up over 20% from its closing price just this past Friday.

Revenue for the quarter was $25 million, compared to $21,000 for the same quarter in 2009. FY revenue came in at $48.1 million, compared to $100,000 the year before.

Mitchell H.

Dendreon (NASDAQ:DNDN) reported Q4 and FY 2010 earnings results Tuesday during the trading day, posting a disappointing loss of $0.64 per share for the quarter, a bigger loss than the $0.49 analysts were projecting on average. Net

Health care shares are higher Monday. Bloomberg is reporting that a high school teacher in Tasmania is suing Johnson & Johnson over an implanted hip-replacement device that stopped selling in Australia due to defects. Meanwhil

Salix is plunging 22% in pre-market trade, after announcing that based on a telephone conversation with the U.S. FDA held last evening, the company anticipates receiving a Complete Response Letter on or before March 7. That's the

Healthcare stocks show mixed direction this morning. But some big declines are seen from Salix Pharmaceuticals, Ltd. (SLXP) and HeartWare International, Inc. (HTWR)

The trial found patients taking the drug experienced a 17% relative improvement in their ability to force air out of their lungs in one second, a common measure of success in treating lung disease, compared with those on a placebo

Vertex's trial would have been deemed a success if it had delivered just a 4.5% improvement in the lung function test.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up over 14% today, after it announced positive clinical trial results for its cystic fibrosis fighting drug VX-770.

The company sees 2011 EPS estimates to $3.38 to $3.40, from $3.38 to $3.44 per share, vs.

Medtronic (NYSE:MDT) reported Q3 EPS of $0.86, ahead of consensus estimates of $0.84 per share. Revenues for the quarter rose 3% year-over-year to $3.96 billion, missing consensus estimates of $3.97 billion.

President and Chief Executive Officer of Seattle Genetics, commented: "The strong brentuximab vedotin data we reported during the fourth quarter of 2010 highlighted an important year for Seattle Genetics, and position the company

Seattle Genetics (NASDAQ:SGEN) reported a Q4 loss of $0.34 per share, narrower than consensus estimates for a loss of $0.38 per share. Revenues for the quarter fell 63% year-over-year to $8.1 million, missing consensus estimates o

The SAN drug Multaq, used by patients with atrial flutter and atrial fibrillation, or irregular heart rhythms to prevent strokes, has been reported to have caused liver damage in at least two female patients who were approximately

Multaq was approved in July 2009 by the FDA, and half a million prescriptions have been written for the drug ever since.

Sanofi offices in Bridgewater, N.J.

The U.S. Food and Drug Administration has recently released a warning to doctors and patients that Sanofi-Aventis' (SAN) heart drug has been linked to liver damage in several patients.